High Growth Rate of Pancreatic Ductal Adenocarcinoma in CDKN2A-p16-Leiden Mutation Carriers

Isaura S Ibrahim, Martin N Wasser, Yinghui Wu, Akin Inderson, Wouter H de Vos Tot Nederveen Cappel, Hans Morreau, Frederik J Hes, Roeland A Veenendaal, Hein Putter, Shirin Feshtali, Anneke M van Mil, Nelleke A Gruis, Rob A Tollenaar, Wilma Bergman, Bert A Bonsing, Hans F A Vasen

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

CDKN2A-p16-Leiden mutation carriers have a 20% to 25% risk of developing pancreatic ductal adenocarcinoma (PDAC). Better understanding of the natural course of PDAC might allow the surveillance protocol to be improved. The aims of the study were to evaluate the role of cystic precursor lesions in the development of PDAC and to assess the growth rate. In 2000, a surveillance program was initiated, consisting of annual MRI in carriers of a CDKN2A-p16-Leiden mutation. The study cohort included 204 (42% male) patients. Cystic precursor lesions were found in 52 (25%) of 204 mutation carriers. Five (9.7%) of 52 mutation carriers with cystic lesions and 8 (7.0%) of 114 mutation carriers without cystic lesions developed PDAC (P ¼ 0.56). Three of 6 patients with a cystic lesion of 10 mm developed PDAC. The median size of all incident PDAC detected between 9 and 12 months since the previous normal MRI was 15 mm, suggesting an annual growth rate of about 15 mm/year. In conclusion, our findings show that patients with and without a cystic lesions have a similar risk of PDAC. However, cystic precursor lesions between 10 and 20 mm increase the risk of PDAC substantially. In view of the large size of the screen-detected tumors, a shorter interval of screening might be recommended for all patients.

Original languageEnglish
Pages (from-to)551-556
Number of pages6
JournalCancer prevention research (Philadelphia, Pa.)
Volume11
Issue number9
DOIs
Publication statusPublished - Sep 2018

Bibliographical note

©2018 American Association for Cancer Research.

Keywords

  • Pancreatic Ductal Adenocarcinoma
  • CDKN2A-p16-Leiden Mutation Carriers
  • risk

Fingerprint Dive into the research topics of 'High Growth Rate of Pancreatic Ductal Adenocarcinoma in CDKN2A-p16-Leiden Mutation Carriers'. Together they form a unique fingerprint.

Cite this